Kintara Therapeutics Total Current Liabilities 2010-2024 | HURA

Kintara Therapeutics total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.

Kintara Therapeutics Total Current Liabilities 2010-2024 | HURA

Kintara Therapeutics total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.2B
Vertex Pharmaceuticals (VRTX)$123.4B
Gilead Sciences (GILD)$107.4B
Regeneron Pharmaceuticals (REGN)$106.8B
Bristol Myers Squibb (BMY)$105.7B
CSL (CSLLY)$97.7B
GSK (GSK)$79.1B
Alnylam Pharmaceuticals (ALNY)$37.5B
Argenex SE (ARGX)$33.5B
Biogen (BIIB)$26.9B
BioNTech SE (BNTX)$26.5B
Illumina (ILMN)$23.1B
BeiGene (BGNE)$21.4B
Moderna (MRNA)$20.7B
Genmab (GMAB)$15.1B
BioMarin Pharmaceutical (BMRN)$13.3B
Vaxcyte (PCVX)$12.9B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.6B
Insmed (INSM)$12.4B
Sarepta Therapeutics (SRPT)$12.1B
Bio-Techne Corp (TECH)$11.2B
QIAGEN (QGEN)$9.6B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8.4B
Exelixis (EXEL)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Revolution Medicines (RVMD)$8B
Legend Biotech (LEGN)$7.9B